PFA BM Outcome
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ajanta Pharma reported strong Q4 FY2026 results with revenue of Rs. 1,422 crore (up 21% YoY) and PAT of Rs. 267 crore (up 18% YoY). For the full year FY2026, revenue stood at Rs. 5,453 crore (up 17%) and PAT at Rs. 1,056 crore (up 15%). EBITDA margin was 26% for FY2026, with mark-to-market forex loss of Rs. 103 crore impacting results. The US Generic segment showed exceptional 49% growth to Rs. 1,557 crore. ROCE remained healthy at 33% and RONW at 25%. Statutory auditors issued unmodified opinion on both consolidated and standalone results. The Income Tax Department conducted search operations in August 2025 and issued a notice under Section 158BC for block period April 2019 to November 2025; impact is not yet ascertainable.
Strong operational performance with revenue and profit growth; however, forex losses and potential tax liability uncertainty warrant monitoring. The unmodified audit opinion provides credibility to the financial results.